Is Medlinker profitable in 2026?

Medlinker has not disclosed profitability figures; it is privately held with no audited financials public. By contrast, rival Ping An Good Doctor reported a profit of RMB379.5 million for 2025, up 366.1% year over year, as of March 24, 2026, highlighting the gap versus a disclosed profitable peer.

Has Medlinker raised new funding recently?

No primary funding round has been reported since its December 2021 Series E, when Sino Biopharmaceutical invested $514 million for a 13% stake at roughly a $4 billion valuation. The most recent disclosed ownership event is a December 2023 secondary transaction with VanMul Health, not a fresh primary round.

Could AI replace Medlinker's diagnosis service?

Medlinker says its MedGPT model is the first generative AI algorithm approved in China for disease diagnosis and treatment recommendation, routing AI output through licensed physicians. Company claims an 84.4% diagnostic relevance rate in April 2025 testing, though this figure is company-reported and not independently verified.

Who is Medlinker's biggest competitor?

Ping An Good Doctor (HKEX: 1833) is the clearest incumbent threat, reporting RMB5.47 billion in 2025 revenue and a swing to RMB379.5 million profit as of March 24, 2026. WeDoctor, which filed for a Hong Kong IPO in April 2026 at a proposed $7 billion valuation, is also closing the gap.

Is Medlinker planning an IPO?

No IPO filing or listing plan for Medlinker has been found as of July 2026. This contrasts with peer WeDoctor, which filed an HKEX IPO application in April 2026 at a proposed $7 billion valuation, leaving Medlinker's 2021 valuation without a visible liquidity path.

Medlinker is privately held and VC-backed, founded in June 2014 by Dr. Wang Shirui, who remains CEO. Key investors include Tencent, Sequoia Capital China, China Investment Corp, and Sino Biopharmaceutical, which invested $514 million for a 13% stake in December 2021.

China · China

Medlinker

Chinese online health platform with an AI doctor product and internet-hospital license.

Protection under test

Assessed 29 July 2026 · Evidence as of 29 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 29 July 2026 · Checkable from H1 2026 · Every call on the record Checkpoint: WeDoctor's IPO progress and Ping An Good Doctor's next earnings report

The call

Medlinker's regulatory paperwork matches its biggest rivals, but its valuation has sat frozen since 2021 while WeDoctor moves toward a public listing.

Medlinker is a Chinese company that uses AI to help doctors diagnose patients over the internet. It has special government licenses that other health apps need, but so do its competitors like Ping An Good Doctor and WeDoctor, which are raising money and going public while Medlinker has not raised funding since 2021. The question is whether Medlinker can raise new money or go public soon, because if it stays quiet while other companies grow and AI tools get better at simple health questions, it will fall further behind.

Why

AI pressure: DeepSeek, Qwen, Moonshot and other free Chinese LLMs doing symptom checks. Free general-purpose LLMs already answer basic symptom questions, pulling users away from Medlinker's triage funnel. Could AI do the core job? Only partly.

Bigger players: Ping An Good Doctor and WeDoctor. Ping An Good Doctor is profitable and public; WeDoctor is filing to IPO near $7B, both chasing the same telehealth users. Could a giant copy it? Probably.

What protects it. Medlinker holds China's internet-hospital license and a regulator-approved AI-diagnosis model, a bar every serious rival also has to clear.

What would change this call

Medlinker announces a primary funding round or files for IPO within 12 months. Would show capital markets still value Medlinker despite 4.5 years without a raise.
WeDoctor completes its IPO filing and lists on a public exchange. Would show a direct peer securing capital and liquidity Medlinker still lacks.
Ping An Good Doctor reports FY2025/2026 results showing growth in chronic-disease or corporate-health segments. Would show a profitable rival expanding share in niches Medlinker also targets.

Key numbers

Series E raised $514M, valuing Medlinker near $4B (2021-12-14)
No primary funding round announced in over 4 years (2025-11)
WeDoctor filed for IPO valued around $7B (2026-04)

Named risks

No primary funding round since December 2021 while peers WeDoctor and others pursue IPOs in 2026. Severity: high
Regulatory/licensing moat is shared by Ping An, Ali Health, and JD Health, not Medlinker-specific. Severity: high
Traction and AI-performance claims are almost entirely company-sourced and unverified by third parties. Severity: medium
Prix Galien USA 2025 nomination was not a win, revealing a gap between marketing claims and independent recognition. Severity: medium
Tightening of China's AI-diagnosis regulation could undercut MedGPT's core regulatory advantage. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Ping An Good Doctor	losing to	Reported RMB379.5M profit, +366.1% YoY, for 2025 as of March 24, 2026, versus Medlinker's undisclosed financials
WeDoctor	losing to	Filed HKEX IPO application at $7B valuation in April 2026 while Medlinker has raised no primary capital since Dec 2021
Ali Health and JD Health	losing to	Leverage captive Alibaba/JD.com distribution that Medlinker lacks, per June 2026 industry analysis
Haodf	contesting	Haodf held ~270,000 registered doctors as of July 2023, competing directly for physician network share
Frontier LLMs (GPT-4V-class, DeepSeek, Qwen)	contesting	Generalist multimodal models increasingly automate symptom-checking, pressuring Medlinker's triage funnel since 2023

Questions people ask

Is Medlinker profitable in 2026?: Medlinker has not disclosed profitability figures; it is privately held with no audited financials public. By contrast, rival Ping An Good Doctor reported a profit of RMB379.5 million for 2025, up 366.1% year over year, as of March 24, 2026, highlighting the gap versus a disclosed profitable peer.
Has Medlinker raised new funding recently?: No primary funding round has been reported since its December 2021 Series E, when Sino Biopharmaceutical invested $514 million for a 13% stake at roughly a $4 billion valuation. The most recent disclosed ownership event is a December 2023 secondary transaction with VanMul Health, not a fresh primary round.
Could AI replace Medlinker's diagnosis service?: Medlinker says its MedGPT model is the first generative AI algorithm approved in China for disease diagnosis and treatment recommendation, routing AI output through licensed physicians. Company claims an 84.4% diagnostic relevance rate in April 2025 testing, though this figure is company-reported and not independently verified.
Who is Medlinker's biggest competitor?: Ping An Good Doctor (HKEX: 1833) is the clearest incumbent threat, reporting RMB5.47 billion in 2025 revenue and a swing to RMB379.5 million profit as of March 24, 2026. WeDoctor, which filed for a Hong Kong IPO in April 2026 at a proposed $7 billion valuation, is also closing the gap.
Is Medlinker planning an IPO?: No IPO filing or listing plan for Medlinker has been found as of July 2026. This contrasts with peer WeDoctor, which filed an HKEX IPO application in April 2026 at a proposed $7 billion valuation, leaving Medlinker's 2021 valuation without a visible liquidity path.
Who owns Medlinker?: Medlinker is privately held and VC-backed, founded in June 2014 by Dr. Wang Shirui, who remains CEO. Key investors include Tencent, Sequoia Capital China, China Investment Corp, and Sino Biopharmaceutical, which invested $514 million for a 13% stake in December 2021.

Timeline

2026-04Rival WeDoctor filed HKEX IPO application at proposed $7B valuation
2026-03-24Ping An Good Doctor reported 2025 profit of RMB379.5M, up 366.1% YoY
2026-03Medlinker announced insurance partnership with Taikang Life for AI consultations
2026-01Medlinker says Future Doctor benchmark paper published in npj Digital Medicine
2025-08Medlinker claims MedGPT outperformed OpenAI's o3 on medical benchmarks (arXiv)
2025-05-01Medlinker launched Future Doctor, billed as China's first AI-doctor application-level product
2025-04Medlinker reports MedGPT achieved 84.4% diagnostic relevance rate in real-patient testing
2023-12Secondary transaction with VanMul Health, most recent disclosed ownership event
2021-12-14Sino Biopharmaceutical invests $514M; merger with Tencent Doctorwork values group at ~$5B
2018-08-01Medlinker reaches unicorn status after RMB1B Series D led by China Investment Corp

Revision history

29 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Alibaba Group JD.com ROX Motor